Artificial Intelligence (AI) in Pharmaceuticals: Global Markets
This report on the global market for AI in pharmaceuticals explores market dynamics and trends, and analyzes technological developments, software performance, clinical trials, new product approvals and emerging technologies. The report also includes profiles of leading companies and their strategies.
The report explores how AI is transforming the pharmaceutical industry through enhanced diagnostic capabilities, early disease detection, clinical trial optimization, drug discovery and personalized treatment planning. It also examines AI disruption across industry verticals and value chain stages, while presenting market spending patterns, investment forecasts, R&D expenditures and venture capital funding. The report segments the market by product type, application and region. Types include software and services. Applications include drug discovery and development, clinical trials, personalized medicines and others. The four regions covered are North America, Europe, Asia-Pacific and the Rest of the World. For market estimates, data has been provided for 2024 as the base year, with forecasts for 2025 through 2030.
Report Includes
The global market for artificial intelligence (AI) in pharmaceuticals is estimated to grow from $3.8 billion in 2025 to reach $15.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 31.7% from 2025 through 2030.
In the pharmaceutical industry, AI is no longer a futuristic concept but a strategic imperative, transforming everything from early-stage drug discovery, where it drastically accelerates target identification and molecule design, to optimizing clinical trials by enhancing patient recruitment and predicting outcomes. Beyond R&D, AI is streamlining manufacturing processes through predictive maintenance and quality control (QC), and revolutionizing supply chain management with accurate demand forecasting and real-time inventory optimization, ultimately leading to faster time-to-market, reduced costs, and the promise of more personalized therapies for patients. While challenges remain in data integration, regulatory frameworks and expertise acquisition, the demonstrable benefits and expanding use cases underscore a qualitative market trend toward AI as a foundational technology for innovation and competitive advantage in pharma.
The report explores how AI is transforming the pharmaceutical industry through enhanced diagnostic capabilities, early disease detection, clinical trial optimization, drug discovery and personalized treatment planning. It also examines AI disruption across industry verticals and value chain stages, while presenting market spending patterns, investment forecasts, R&D expenditures and venture capital funding. The report segments the market by product type, application and region. Types include software and services. Applications include drug discovery and development, clinical trials, personalized medicines and others. The four regions covered are North America, Europe, Asia-Pacific and the Rest of the World. For market estimates, data has been provided for 2024 as the base year, with forecasts for 2025 through 2030.
Report Includes
- 27 data tables and 62 additional tables
- An analysis of the global markets for artificial intelligence (AI) in the pharmaceuticals industry
- Analyses of the global market trends, with historic revenue (sales figures) from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
- Estimates of the market’s size and revenue growth prospects, accompanied by a market share analysis by product type, application and region
- Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
- Insights derived from Porter’s Five Forces model, as well as a global supply chain analysis
- Case studies on AI implementation to streamline processes across drug discovery and development, manufacturing, quality control and patient care
- A relevant patent analysis, featuring key granted and published patents
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- Analysis of the industry structure, including companies’ market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Google DeepMind, Atomwise Inc., Insilico Medicine, Recursion Pharmaceuticals and Nvidia Corp.
The global market for artificial intelligence (AI) in pharmaceuticals is estimated to grow from $3.8 billion in 2025 to reach $15.2 billion by the end of 2030, at a compound annual growth rate (CAGR) of 31.7% from 2025 through 2030.
In the pharmaceutical industry, AI is no longer a futuristic concept but a strategic imperative, transforming everything from early-stage drug discovery, where it drastically accelerates target identification and molecule design, to optimizing clinical trials by enhancing patient recruitment and predicting outcomes. Beyond R&D, AI is streamlining manufacturing processes through predictive maintenance and quality control (QC), and revolutionizing supply chain management with accurate demand forecasting and real-time inventory optimization, ultimately leading to faster time-to-market, reduced costs, and the promise of more personalized therapies for patients. While challenges remain in data integration, regulatory frameworks and expertise acquisition, the demonstrable benefits and expanding use cases underscore a qualitative market trend toward AI as a foundational technology for innovation and competitive advantage in pharma.
CHAPTER 1 EXECUTIVE SUMMARY
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
CHAPTER 2 MARKET OVERVIEW
Current Market Overview
Macroeconomic Factors Analysis
Government Policy and Regulation
Technological Infrastructure and Digital Readiness
Global Trade and Supply Chain Dynamics
Impact of U.S. Tariffs
Porter's Five Forces Analysis
Potential for New Entrants (Moderate to High)
Bargaining Power of Suppliers (Low to Moderate)
Bargaining Power of Buyers (High)
Threat of Substitute Products or Services (Low to Moderate)
Industry Level of Competitiveness (High)
AI's Impact on the Pharmaceutical Value Chain
Drug Discovery and Preclinical Development: Accelerated Innovation
Clinical Trials: Smarter Design and Execution
Manufacturing and Supply Chain: Intelligent Operations
Regulatory Affairs and Compliance: Automation and Accuracy
Commercialization and Market Access: Data-Driven Strategies
Post-Market Surveillance: Continuous Learning and Safety Monitoring
Use Cases
Use Case 1: Generative AI for Efficiency in Regulatory Submissions
Use Case 2: Generative AI-Enabled R&D Assistant for Synthesis Routes
CHAPTER 3 MARKET DYNAMICS
Market Dynamics
Market Drivers
Faster Drug Discovery and Development
Increasing Adoption of AI in Clinical Trials
Demand for Precision Medicine and AI Applications
Market Restraints
Regulatory and Ethical Concerns
Data Challenges
Market Opportunities
Collaborations and Investments
Increased Focus on Drug Discovery in Emerging Nations
Advances of Generative AI in Molecular Design
CHAPTER 4 REGULATORY LANDSCAPE
Overview
Regulatory Scenario in the U.S.
Regulatory Scenario in Europe
Regulatory Scenario in Japan
Regulatory Scenario in China
Other Countries
CHAPTER 5 EMERGING TRENDS AND PIPELINE ANALYSIS
Emerging Trends
Generative AI in Pharma
Federated Learning
Natural Language Processing
Generative Adversarial Networks
Pipeline Analysis
Takeaways
Patent Analysis
Findings
CHAPTER 6 MARKET SEGMENT ANALYSIS
Segmentation Breakdown
Market Breakdown, by Product Type
Takeaways
Software
Services
Market Breakdown, by Application
Takeaways
Drug Discovery and Development
Clinical Trials
Personalized Medicine
Other Applications
Geographic Breakdown
Market Breakdown, by Region
Takeaways
North America
Europe
Asia-Pacific
Rest of the World (RoW)
CHAPTER 7 COMPETITIVE INTELLIGENCE
Takeaways
Competitive Analysis
Strategic Analysis
Investment Landscape
CHAPTER 8 SUSTAINABILITY IN AI IN THE PHARMACEUTICAL INDUSTRY: ESG PERSPECTIVE
Introduction to ESG
Sustainability Trends and Initiatives
ESG Risk Ratings
Concluding Remarks from BCC Research
CHAPTER 9 APPENDIX
Research Methodology
Sources
Abbreviations
Company Profiles
AICURE
ATOMWISE INC.
BENEVOLENTAI
GOOGLE DEEPMIND
HEALX
IKTOS
INSILICO MEDICINE
INVENIAI LLC.
NVIDIA CORP.
PATHAI INC.
RECURSION
SCHRODINGER INC.
SYRENCLOUD INC.
TEMPUS AI INC.
XTALPI INC.
Emerging Start-ups/Market Disruptors
Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion
CHAPTER 2 MARKET OVERVIEW
Current Market Overview
Macroeconomic Factors Analysis
Government Policy and Regulation
Technological Infrastructure and Digital Readiness
Global Trade and Supply Chain Dynamics
Impact of U.S. Tariffs
Porter's Five Forces Analysis
Potential for New Entrants (Moderate to High)
Bargaining Power of Suppliers (Low to Moderate)
Bargaining Power of Buyers (High)
Threat of Substitute Products or Services (Low to Moderate)
Industry Level of Competitiveness (High)
AI's Impact on the Pharmaceutical Value Chain
Drug Discovery and Preclinical Development: Accelerated Innovation
Clinical Trials: Smarter Design and Execution
Manufacturing and Supply Chain: Intelligent Operations
Regulatory Affairs and Compliance: Automation and Accuracy
Commercialization and Market Access: Data-Driven Strategies
Post-Market Surveillance: Continuous Learning and Safety Monitoring
Use Cases
Use Case 1: Generative AI for Efficiency in Regulatory Submissions
Use Case 2: Generative AI-Enabled R&D Assistant for Synthesis Routes
CHAPTER 3 MARKET DYNAMICS
Market Dynamics
Market Drivers
Faster Drug Discovery and Development
Increasing Adoption of AI in Clinical Trials
Demand for Precision Medicine and AI Applications
Market Restraints
Regulatory and Ethical Concerns
Data Challenges
Market Opportunities
Collaborations and Investments
Increased Focus on Drug Discovery in Emerging Nations
Advances of Generative AI in Molecular Design
CHAPTER 4 REGULATORY LANDSCAPE
Overview
Regulatory Scenario in the U.S.
Regulatory Scenario in Europe
Regulatory Scenario in Japan
Regulatory Scenario in China
Other Countries
CHAPTER 5 EMERGING TRENDS AND PIPELINE ANALYSIS
Emerging Trends
Generative AI in Pharma
Federated Learning
Natural Language Processing
Generative Adversarial Networks
Pipeline Analysis
Takeaways
Patent Analysis
Findings
CHAPTER 6 MARKET SEGMENT ANALYSIS
Segmentation Breakdown
Market Breakdown, by Product Type
Takeaways
Software
Services
Market Breakdown, by Application
Takeaways
Drug Discovery and Development
Clinical Trials
Personalized Medicine
Other Applications
Geographic Breakdown
Market Breakdown, by Region
Takeaways
North America
Europe
Asia-Pacific
Rest of the World (RoW)
CHAPTER 7 COMPETITIVE INTELLIGENCE
Takeaways
Competitive Analysis
Strategic Analysis
Investment Landscape
CHAPTER 8 SUSTAINABILITY IN AI IN THE PHARMACEUTICAL INDUSTRY: ESG PERSPECTIVE
Introduction to ESG
Sustainability Trends and Initiatives
ESG Risk Ratings
Concluding Remarks from BCC Research
CHAPTER 9 APPENDIX
Research Methodology
Sources
Abbreviations
Company Profiles
AICURE
ATOMWISE INC.
BENEVOLENTAI
GOOGLE DEEPMIND
HEALX
IKTOS
INSILICO MEDICINE
INVENIAI LLC.
NVIDIA CORP.
PATHAI INC.
RECURSION
SCHRODINGER INC.
SYRENCLOUD INC.
TEMPUS AI INC.
XTALPI INC.
Emerging Start-ups/Market Disruptors
LIST OF TABLES
Summary Table : Global Market for AI in Pharmaceuticals, by Region, Through 2030
Table 1 : Collaborations Between AI Software and Pharmaceutical Companies
Table 2 : FDA AI/ML Initiatives and Milestones, 2014 and 2025
Table 3 : EMA AI/ML Regulatory Development Timeline, 2021–2024
Table 4 : Clinical Trial Data for AI in Pharmaceutical Drugs, 2025
Table 5 : Granted Patents for AI in Pharmaceuticals, 2022–2025
Table 6 : Global Market for AI in Pharmaceuticals, by Product Type, Through 2030
Table 7 : Global Market for AI Software in Pharmaceuticals, by Region, Through 2030
Table 8 : Global Market for Services in AI in Pharmaceuticals, by Region, Through 2030
Table 9 : Global Market for AI in Pharmaceuticals, by Application, Through 2030
Table 10 : AI Tools Used in Drug Discovery
Table 11 : AI-Enabled Drugs Entering the Clinical Phase, 2025
Table 12 : Global Market for AI in Drug Discovery and Development, by Region, Through 2030
Table 13 : Partnerships Between Pharmaceutical and Technology Companies, 2023–2025
Table 14 : Advantages and Disadvantages of Using AI in Clinical Trials
Table 15 : Global Market for AI in Pharmaceuticals for Clinical Trial Applications, by Region, Through 2030
Table 16 : Applications of ML in Pharmacogenomics
Table 17 : Global Market for AI in Pharmaceuticals for Personalized Medicine, by Region, Through 2030
Table 18 : Global Market for Other Applications of AI in Pharmaceuticals, by Region, Through 2030
Table 19 : Global Market for AI in Pharmaceuticals, by Region, Through 2030
Table 20 : North American Market for AI in Pharmaceuticals, by Product Type, Through 2030
Table 21 : North American Market for AI in Pharmaceuticals, by Application, Through 2030
Table 22 : North American Market for AI in Pharmaceuticals, by Country, Through 2030
Table 23 : European Market for AI in Pharmaceuticals, by Product Type, Through 2030
Table 24 : European Market for AI in Pharmaceuticals, by Application, Through 2030
Table 25 : European Market for AI in Pharmaceuticals, by Country, Through 2030
Table 26 : Asia-Pacific Market for AI in Pharmaceuticals, by Product Type, Through 2030
Table 27 : Asia-Pacific Market for AI in Pharmaceuticals, by Application, Through 2030
Table 28 : Asia-Pacific Market for AI in Pharmaceuticals, by Country, Through 2030
Table 29 : RoW Market for AI in Pharmaceuticals, by Product Type, Through 2030
Table 30 : RoW Market for AI in Pharmaceuticals, by Application, Through 2030
Table 31 : RoW Market for AI in Pharmaceuticals, by Sub-Region, Through 2030
Table 32 : Leading Companies in the Global Market for AI in Pharmaceuticals, 2024
Table 33 : Agreements, Collaborations and Partnerships in the Market for AI in Pharmaceuticals, 2022–2025
Table 34 : M&A in the AI in Pharmaceuticals Industry, 2024–2025
Table 35 : Recent Investments in the AI in Pharmaceuticals Industry, 2024 and 2025
Table 36 : ESG Risk Rankings for AI in Pharmaceuticals Companies, 2025*
Table 37 : Information Sources Used in this Report
Table 38 : Abbreviations Used in this Report
Table 39 : AiCure: Company Snapshot
Table 40 : AiCure: Product Portfolio
Table 41 : AiCure: News/Key Developments, 2024
Table 42 : Atomwise Inc.: Company Snapshot
Table 43 : Atomwise Inc.: Product Portfolio
Table 44 : Atomwise Inc.: News/Key Developments, 2022
Table 45 : BenevolentAI: Company Snapshot
Table 46 : BenevolentAI: Product Portfolio
Table 47 : BenevolentAI: News/Key Developments, 2022–2025
Table 48 : Google DeepMind: Company Snapshot
Table 49 : Google DeepMind: Product Portfolio
Table 50 : Google DeepMind: News/Key Developments, 2024 and 2025
Table 51 : Healx: Company Snapshot
Table 52 : Healx: Product Portfolio
Table 53 : Healx: News/Key Developments, 2023 and 2024
Table 54 : Iktos: Company Snapshot
Table 55 : Iktos: Product Portfolio
Table 56 : Iktos: News/Key Developments, 2023–2025
Table 57 : Insilico Medicine: Company Snapshot
Table 58 : Insilico Medicine: Product Portfolio
Table 59 : Insilico Medicine: News/Key Developments, 2023–2025
Table 60 : InveniAI LLC.: Company Snapshot
Table 61 : InveniAI LLC.: Product Portfolio
Table 62 : InveniAI LLC.: News/Key Developments, 2021–2024
Table 63 : Nvidia Corp.: Company Snapshot
Table 64 : Nvidia Corp.: Financial Performance, FY 2023 and 2024
Table 65 : Nvidia Corp.: Product Portfolio
Table 66 : Nvidia Corp.: News/Key Developments, 2023–2025
Table 67 : PathAI Inc.: Company Snapshot
Table 68 : PathAI Inc.: Product Portfolio
Table 69 : PathAI Inc.: News/Key Developments, 2024 and 2025
Table 70 : Recursion: Company Snapshot
Table 71 : Recursion: Financial Performance, FY 2023 and 2024
Table 72 : Recursion: Product Portfolio
Table 73 : Recursion: News/Key Developments, 2024 and 2025
Table 74 : Schr?dinger Inc.: Company Snapshot
Table 75 : Schr?dinger Inc.: Financial Performance, FY 2023 and 2024
Table 76 : Schr?dinger Inc.: Product Portfolio
Table 77 : Schr?dinger Inc.: News/Key Developments, 2023 and 2024
Table 78 : SyrenCloud Inc.: Company Snapshot
Table 79 : SyrenCloud Inc.: Product Portfolio
Table 80 : Tempus AI Inc.: Company Snapshot
Table 81 : Tempus AI Inc.: Financial Performance, FY 2023 and 2024
Table 82 : Tempus AI Inc.: Product Portfolio
Table 83 : Tempus AI Inc.: News/Key Developments, 2023–2025
Table 84 : XtalPi Inc.: Company Snapshot
Table 85 : XtalPi Inc.: Financial Performance, FY 2023 and 2024
Table 86 : XtalPi Inc.: Product Portfolio
Table 87 : XtalPi Inc.: News/ Key Developments, 2024 and 2025
Table 88 : Emerging Startups in the Market for AI in Pharmaceuticals
Summary Table : Global Market for AI in Pharmaceuticals, by Region, Through 2030
Table 1 : Collaborations Between AI Software and Pharmaceutical Companies
Table 2 : FDA AI/ML Initiatives and Milestones, 2014 and 2025
Table 3 : EMA AI/ML Regulatory Development Timeline, 2021–2024
Table 4 : Clinical Trial Data for AI in Pharmaceutical Drugs, 2025
Table 5 : Granted Patents for AI in Pharmaceuticals, 2022–2025
Table 6 : Global Market for AI in Pharmaceuticals, by Product Type, Through 2030
Table 7 : Global Market for AI Software in Pharmaceuticals, by Region, Through 2030
Table 8 : Global Market for Services in AI in Pharmaceuticals, by Region, Through 2030
Table 9 : Global Market for AI in Pharmaceuticals, by Application, Through 2030
Table 10 : AI Tools Used in Drug Discovery
Table 11 : AI-Enabled Drugs Entering the Clinical Phase, 2025
Table 12 : Global Market for AI in Drug Discovery and Development, by Region, Through 2030
Table 13 : Partnerships Between Pharmaceutical and Technology Companies, 2023–2025
Table 14 : Advantages and Disadvantages of Using AI in Clinical Trials
Table 15 : Global Market for AI in Pharmaceuticals for Clinical Trial Applications, by Region, Through 2030
Table 16 : Applications of ML in Pharmacogenomics
Table 17 : Global Market for AI in Pharmaceuticals for Personalized Medicine, by Region, Through 2030
Table 18 : Global Market for Other Applications of AI in Pharmaceuticals, by Region, Through 2030
Table 19 : Global Market for AI in Pharmaceuticals, by Region, Through 2030
Table 20 : North American Market for AI in Pharmaceuticals, by Product Type, Through 2030
Table 21 : North American Market for AI in Pharmaceuticals, by Application, Through 2030
Table 22 : North American Market for AI in Pharmaceuticals, by Country, Through 2030
Table 23 : European Market for AI in Pharmaceuticals, by Product Type, Through 2030
Table 24 : European Market for AI in Pharmaceuticals, by Application, Through 2030
Table 25 : European Market for AI in Pharmaceuticals, by Country, Through 2030
Table 26 : Asia-Pacific Market for AI in Pharmaceuticals, by Product Type, Through 2030
Table 27 : Asia-Pacific Market for AI in Pharmaceuticals, by Application, Through 2030
Table 28 : Asia-Pacific Market for AI in Pharmaceuticals, by Country, Through 2030
Table 29 : RoW Market for AI in Pharmaceuticals, by Product Type, Through 2030
Table 30 : RoW Market for AI in Pharmaceuticals, by Application, Through 2030
Table 31 : RoW Market for AI in Pharmaceuticals, by Sub-Region, Through 2030
Table 32 : Leading Companies in the Global Market for AI in Pharmaceuticals, 2024
Table 33 : Agreements, Collaborations and Partnerships in the Market for AI in Pharmaceuticals, 2022–2025
Table 34 : M&A in the AI in Pharmaceuticals Industry, 2024–2025
Table 35 : Recent Investments in the AI in Pharmaceuticals Industry, 2024 and 2025
Table 36 : ESG Risk Rankings for AI in Pharmaceuticals Companies, 2025*
Table 37 : Information Sources Used in this Report
Table 38 : Abbreviations Used in this Report
Table 39 : AiCure: Company Snapshot
Table 40 : AiCure: Product Portfolio
Table 41 : AiCure: News/Key Developments, 2024
Table 42 : Atomwise Inc.: Company Snapshot
Table 43 : Atomwise Inc.: Product Portfolio
Table 44 : Atomwise Inc.: News/Key Developments, 2022
Table 45 : BenevolentAI: Company Snapshot
Table 46 : BenevolentAI: Product Portfolio
Table 47 : BenevolentAI: News/Key Developments, 2022–2025
Table 48 : Google DeepMind: Company Snapshot
Table 49 : Google DeepMind: Product Portfolio
Table 50 : Google DeepMind: News/Key Developments, 2024 and 2025
Table 51 : Healx: Company Snapshot
Table 52 : Healx: Product Portfolio
Table 53 : Healx: News/Key Developments, 2023 and 2024
Table 54 : Iktos: Company Snapshot
Table 55 : Iktos: Product Portfolio
Table 56 : Iktos: News/Key Developments, 2023–2025
Table 57 : Insilico Medicine: Company Snapshot
Table 58 : Insilico Medicine: Product Portfolio
Table 59 : Insilico Medicine: News/Key Developments, 2023–2025
Table 60 : InveniAI LLC.: Company Snapshot
Table 61 : InveniAI LLC.: Product Portfolio
Table 62 : InveniAI LLC.: News/Key Developments, 2021–2024
Table 63 : Nvidia Corp.: Company Snapshot
Table 64 : Nvidia Corp.: Financial Performance, FY 2023 and 2024
Table 65 : Nvidia Corp.: Product Portfolio
Table 66 : Nvidia Corp.: News/Key Developments, 2023–2025
Table 67 : PathAI Inc.: Company Snapshot
Table 68 : PathAI Inc.: Product Portfolio
Table 69 : PathAI Inc.: News/Key Developments, 2024 and 2025
Table 70 : Recursion: Company Snapshot
Table 71 : Recursion: Financial Performance, FY 2023 and 2024
Table 72 : Recursion: Product Portfolio
Table 73 : Recursion: News/Key Developments, 2024 and 2025
Table 74 : Schr?dinger Inc.: Company Snapshot
Table 75 : Schr?dinger Inc.: Financial Performance, FY 2023 and 2024
Table 76 : Schr?dinger Inc.: Product Portfolio
Table 77 : Schr?dinger Inc.: News/Key Developments, 2023 and 2024
Table 78 : SyrenCloud Inc.: Company Snapshot
Table 79 : SyrenCloud Inc.: Product Portfolio
Table 80 : Tempus AI Inc.: Company Snapshot
Table 81 : Tempus AI Inc.: Financial Performance, FY 2023 and 2024
Table 82 : Tempus AI Inc.: Product Portfolio
Table 83 : Tempus AI Inc.: News/Key Developments, 2023–2025
Table 84 : XtalPi Inc.: Company Snapshot
Table 85 : XtalPi Inc.: Financial Performance, FY 2023 and 2024
Table 86 : XtalPi Inc.: Product Portfolio
Table 87 : XtalPi Inc.: News/ Key Developments, 2024 and 2025
Table 88 : Emerging Startups in the Market for AI in Pharmaceuticals
LIST OF FIGURES
Summary Figure : Global Market Shares of AI in Pharmaceuticals, by Region, 2024
Figure 1 : Applications of AI in the Drug Development and Distribution Life Cycle
Figure 2 : Porter’s Five Forces Analysis: AI in Pharmaceuticals Market
Figure 3 : Applications of AI in the Pharmaceutical Value Chain
Figure 4 : Market Dynamics of AI in Pharmaceuticals
Figure 5 : Emerging Technologies of AI in the Pharmaceutical Market
Figure 6 : Granted Patents for AI in Pharmaceuticals, by Year, 2021–2025
Figure 7 : Global Market Shares of AI in Pharmaceuticals, by Product Type, 2024
Figure 8 : Global Market Shares of AI Software in Pharmaceuticals, by Region, 2024
Figure 9 : Global Market Shares of Services for AI in Pharmaceuticals, by Region, 2024
Figure 10 : Global Market Shares of AI in Pharmaceuticals, by Application, 2024
Figure 11 : Role of AI in Drug Discovery
Figure 12 : Global Market Shares of AI in Drug Discovery and Development, by Region, 2024
Figure 13 : Global Market Shares of AI in Pharmaceuticals for Clinical Trial Applications, by Region, 2024
Figure 14 : Global Market Shares of AI in AI in Pharmaceuticals for Personalized Medicine, by Region, 2024
Figure 15 : Global Market Shares of Other Applications of AI in Pharmaceuticals, by Region, 2024
Figure 16 : Global Market Shares of AI in Pharmaceuticals, by Region, 2024
Figure 17 : North American Market Shares of AI in Pharmaceuticals, by Product Type, 2024
Figure 18 : North American Market Shares of AI in Pharmaceuticals, by Application, 2024
Figure 19 : North American Market Shares of AI in Pharmaceuticals, by Country, 2024
Figure 20 : European Market Shares of AI in Pharmaceuticals, by Product Type, 2024
Figure 21 : European Market Shares of AI in Pharmaceuticals, by Application, 2024
Figure 22 : European Market Shares of AI in Pharmaceuticals, by Country, 2024
Figure 23 : Asia-Pacific Market Shares of AI in Pharmaceuticals, by Product Type, 2024
Figure 24 : Asia-Pacific Market Shares of AI in Pharmaceuticals, by Application, 2024
Figure 25 : Asia-Pacific Market Shares of AI in Pharmaceuticals, by Country, 2024
Figure 26 : RoW Market Shares of AI in Pharmaceuticals, by Product Type, 2024
Figure 27 : RoW Market Shares of AI in Pharmaceuticals, by Application, 2024
Figure 28 : RoW Market Shares of AI in Pharmaceuticals, by Sub-Region, 2024
Figure 29 : Biopharma AI Investment, 2019–2024
Figure 30 : Nvidia Corp.: Revenue Share, by Business Unit, FY 2024
Figure 31 : Nvidia Corp.: Revenue Share by Country/Region, FY 2024
Figure 32 : Schr?dinger Inc.: Revenue Share, by Business Unit, FY 2024
Figure 33 : Schr?dinger Inc.: Revenue Share, by Country/Region, FY 2024
Figure 34 : Tempus AI Inc.: Revenue Share, by Business Unit, FY 2024
Figure 35 : XtalPi Inc.: Revenue Share, by Business Unit, FY 2024
Figure 36 : XtalPi Inc.: Revenue Share, by Country/Region, FY 2024
Summary Figure : Global Market Shares of AI in Pharmaceuticals, by Region, 2024
Figure 1 : Applications of AI in the Drug Development and Distribution Life Cycle
Figure 2 : Porter’s Five Forces Analysis: AI in Pharmaceuticals Market
Figure 3 : Applications of AI in the Pharmaceutical Value Chain
Figure 4 : Market Dynamics of AI in Pharmaceuticals
Figure 5 : Emerging Technologies of AI in the Pharmaceutical Market
Figure 6 : Granted Patents for AI in Pharmaceuticals, by Year, 2021–2025
Figure 7 : Global Market Shares of AI in Pharmaceuticals, by Product Type, 2024
Figure 8 : Global Market Shares of AI Software in Pharmaceuticals, by Region, 2024
Figure 9 : Global Market Shares of Services for AI in Pharmaceuticals, by Region, 2024
Figure 10 : Global Market Shares of AI in Pharmaceuticals, by Application, 2024
Figure 11 : Role of AI in Drug Discovery
Figure 12 : Global Market Shares of AI in Drug Discovery and Development, by Region, 2024
Figure 13 : Global Market Shares of AI in Pharmaceuticals for Clinical Trial Applications, by Region, 2024
Figure 14 : Global Market Shares of AI in AI in Pharmaceuticals for Personalized Medicine, by Region, 2024
Figure 15 : Global Market Shares of Other Applications of AI in Pharmaceuticals, by Region, 2024
Figure 16 : Global Market Shares of AI in Pharmaceuticals, by Region, 2024
Figure 17 : North American Market Shares of AI in Pharmaceuticals, by Product Type, 2024
Figure 18 : North American Market Shares of AI in Pharmaceuticals, by Application, 2024
Figure 19 : North American Market Shares of AI in Pharmaceuticals, by Country, 2024
Figure 20 : European Market Shares of AI in Pharmaceuticals, by Product Type, 2024
Figure 21 : European Market Shares of AI in Pharmaceuticals, by Application, 2024
Figure 22 : European Market Shares of AI in Pharmaceuticals, by Country, 2024
Figure 23 : Asia-Pacific Market Shares of AI in Pharmaceuticals, by Product Type, 2024
Figure 24 : Asia-Pacific Market Shares of AI in Pharmaceuticals, by Application, 2024
Figure 25 : Asia-Pacific Market Shares of AI in Pharmaceuticals, by Country, 2024
Figure 26 : RoW Market Shares of AI in Pharmaceuticals, by Product Type, 2024
Figure 27 : RoW Market Shares of AI in Pharmaceuticals, by Application, 2024
Figure 28 : RoW Market Shares of AI in Pharmaceuticals, by Sub-Region, 2024
Figure 29 : Biopharma AI Investment, 2019–2024
Figure 30 : Nvidia Corp.: Revenue Share, by Business Unit, FY 2024
Figure 31 : Nvidia Corp.: Revenue Share by Country/Region, FY 2024
Figure 32 : Schr?dinger Inc.: Revenue Share, by Business Unit, FY 2024
Figure 33 : Schr?dinger Inc.: Revenue Share, by Country/Region, FY 2024
Figure 34 : Tempus AI Inc.: Revenue Share, by Business Unit, FY 2024
Figure 35 : XtalPi Inc.: Revenue Share, by Business Unit, FY 2024
Figure 36 : XtalPi Inc.: Revenue Share, by Country/Region, FY 2024
